QTREX Quantum grants 550,000 RSUs to CBO

Rozanovich Yoav reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 07/14/2026 - 05:45 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Rozanovich Yoav reported acquisition or exercise transactions in this Form 4 filing.

QTREX Quantum Ltd. granted Chief Business Officer Yoav Rozanovich an equity award covering 550,000 Ordinary Shares on July 6, 2026, recorded at $0.0000 per share.

The award consists of Restricted Share Units, with 183,334 RSUs vesting on October 1, 2026 and the remaining RSUs vesting on a quarterly basis over two years after that date.

Insider Trade Summary

Grant/Award: 550,000 shares

Grant/Award 1 txn

Insider Rozanovich Yoav

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1	550,000	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 550,000 shares (Direct)

Footnotes (1)

1. F1. The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: 183,334 RSUs will vest on October 1, 2026, and the remaining RSUs will vest on a quarterly basis over two years following the first vesting event.

Key Figures

Equity award shares: 550,000 Ordinary Shares Grant price per share: $0.0000 per share First vesting tranche: 183,334 RSUs +2 more

5 metrics

Equity award shares 550,000 Ordinary Shares Grant to Chief Business Officer Yoav Rozanovich on July 6, 2026

Grant price per share $0.0000 per share Recorded transaction price for the equity award

First vesting tranche 183,334 RSUs Scheduled to vest on October 1, 2026

Remaining vesting period 2 years Remaining RSUs vest quarterly over two years after October 1, 2026

Post-grant holdings 550,000 shares Total shares reported as held directly after the transaction

Key Terms

Restricted Share Units, 2019 Plan, vesting, Ordinary Shares

4 terms

Restricted Share Units financial

"The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s 2019 Plan"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2019 Plan financial

"RSUs were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan"

vesting financial

"will vest according to the following schedule: 183,334 RSUs will vest on October 1, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Ordinary Shares financial

"security_title is listed as Ordinary Shares for the reported transaction"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did QTREX Quantum Ltd. (QTEX) report for Yoav Rozanovich?

QTREX Quantum reported that Chief Business Officer Yoav Rozanovich received an equity award covering 550,000 Ordinary Shares as Restricted Share Units. The grant was dated July 6, 2026 and recorded at a price of $0.0000 per share.

How many QTEX shares were granted to the chief business officer in this Form 4?

The chief business officer of QTREX Quantum, Yoav Rozanovich, was granted an award covering 550,000 Ordinary Shares. These shares are in the form of Restricted Share Units and are subject to a multi-year vesting schedule rather than being fully vested immediately.

What is the vesting schedule for the 550,000 RSUs reported by QTEX?

The vesting schedule provides that 183,334 RSUs will vest on October 1, 2026. The remaining RSUs from the 550,000-unit award will then vest on a quarterly basis over the following two years after that initial vesting date.

At what price were the QTEX Restricted Share Units granted to Yoav Rozanovich?

The equity award was reported with a transaction price of $0.0000 per share. This reflects that the Restricted Share Units were granted as part of compensation rather than purchased in an open-market transaction for cash consideration.

How many QTEX shares does Yoav Rozanovich hold after this reported transaction?

After the grant, Yoav Rozanovich is reported as holding 550,000 shares directly. This figure represents his total reported holdings following the equity award covered by the Form 4 filing on July 6, 2026.

Under which equity plan were the QTEX RSUs granted to the chief business officer?

The Restricted Share Units were granted under Qtrex Quantum Ltd.'s 2019 Plan, described as the company’s equity incentive plan. The footnote notes that the issuer was formerly known as Insense Medical before adopting the current name.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rozanovich Yoav

(Last) (First) (Middle)

2 HA-TIDHAR ST.

(Street)

RA'ANANA 4366504

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
QTREX Quantum Ltd. [ QTEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/06/2026		A		550,000(1)	A	$0	550,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: 183,334 RSUs will vest on October 1, 2026, and the remaining RSUs will vest on a quarterly basis over two years following the first vesting event.

	/s/ Yoav Rozanovich	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)